Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Fineline Cube Aug 3, 2026
Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Fineline Cube Aug 3, 2026
Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Fineline Cube Aug 3, 2026
Company Drug

Kexing Biopharm’s GB18 Receives FDA Approval for Tumor Cachexia Clinical Trial

Fineline Cube May 22, 2025

China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced receiving clinical trial approval from the US...

Company Drug

Accropeutics’ AC-201 Shows Positive Phase II Results in Psoriasis Treatment

Fineline Cube May 22, 2025

Suzhou-based Accropeutics Bioscience announced positive results from a Phase II study for its AC-201 in...

Company Drug

Simcere’s FGFR2b-Targeting ADC SIM0686 Enters Phase I Clinical Study

Fineline Cube May 22, 2025

China-based Simcere Pharmaceutical Group (HKG: 2096) announced the initiation of a Phase I clinical study...

Company Drug

Triastek’s T22 Gastric Retention Capsules Gain NMPA IND Clearance

Fineline Cube May 22, 2025

Nanjing-based Triastek Inc., a pioneer in 3D-printed pharmaceutical formulations, has obtained Investigational New Drug (IND)...

Company Drug

Boehringer Ingelheim’s Metalyse Approved in China for Acute Ischemic Stroke

Fineline Cube May 22, 2025

Germany-based pharmaceutical leader Boehringer Ingelheim announced receiving marketing approval from China’s National Medical Products Administration...

Company

Well Lead Medical to Set Up Subsidiary and Manufacturing Base in Indonesia

Fineline Cube May 22, 2025

Guangzhou-based medical catheter specialist Well Lead Medical Co., Ltd (SHA: 603309) plans to establish a...

Company Drug

Kelun-Biotech’s Sacituzumab Tirumotecan Accepted for NMPA Review for HR+, HER2- Breast Cancer

Fineline Cube May 22, 2025

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) announced that another indication approval filing for its...

Company Deals

Shandong Buchang Pharmaceuticals Partners with FBC for MF59 Adjuvant R&D

Fineline Cube May 22, 2025

China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) announced plans to enter into an Entrusted...

Policy / Regulatory

HHS Implements Trump’s Order for Most-Favored-Nation Drug Pricing

Fineline Cube May 22, 2025

The U.S. Department of Health and Human Services (HHS) announced that it is taking immediate...

Company Drug

Nuance Pharma’s Ohtuvayre Meets Primary Endpoints in COPD Study

Fineline Cube May 22, 2025

China-based Nuance Pharma announced positive topline results from the ENHANCE-CHINA study (NCT05743075) for its nebulized...

Company Drug

AccurEdit Therapeutics’ ART001 Receives FDA RMAT Designation for ATTR

Fineline Cube May 22, 2025

China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd announced receiving Regenerative Medicine Advanced...

Company Deals

AstraZeneca Completes Acquisition of EsoBiotec for Up to USD 1 Billion

Fineline Cube May 22, 2025

UK-based major AstraZeneca (AZ; NASDAQ: AZN) announced the completion of its acquisition of EsoBiotec SA,...

Company Deals

Pulnovo Medical Raises Tens of Millions in New Financing Round

Fineline Cube May 21, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for hypertension and heart failure, announced...

Company Deals Medical Device

PHASE Scientific Completes Series A Financing to Advance Urine-Based Diagnostics

Fineline Cube May 21, 2025

Hong Kong-based urine-based diagnostics specialist PHASE Scientific International Limited announced the completion of a Series...

Policy / Regulatory

China’s CDE Announces 94th Batch of Reference Preparations for Generic Evaluation

Fineline Cube May 21, 2025

China’s Center for Drug Evaluation (CDE) has selected the 94th batch of reference preparations for...

Company Deals

Merck KGaA Partners with IMEC to Develop Advanced Microphysiological Systems Platform

Fineline Cube May 21, 2025

German major Merck KGaA (ETR: MRK) this week announced a partnership with Belgium-based Interuniversity Microelectronics Centre...

Company Deals Drug

Antengene and MSD Collaborate on ATG-022 for Advanced Solid Tumors

Fineline Cube May 21, 2025

China-based Antengene Corporation Limited (HKG: 6996) has entered into a collaboration with US major Merck,...

Hospital Policy / Regulatory

China’s County Hospitals Show Improved Medical Service Capability in 2024

Fineline Cube May 21, 2025

The National Health Commission (NHC) released a notice reporting the status of the county hospital...

Company Drug

3SBio Registers Phase III Study for SSGJ-707 in Advanced NSCLC

Fineline Cube May 21, 2025

China-based 3SBio Inc. (HKG: 1530) announced this week the registration of the first Phase III...

Company Drug

Ascletis Pharma Initiates ASC47-103 Study in US for Obesity Treatment

Fineline Cube May 21, 2025

China-based Ascletis Pharma Inc. (HKG: 1672) announced the first subject dosing of the ASC47-103 study...

Posts pagination

1 … 194 195 196 … 702

Recent updates

  • BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative
  • Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway
  • China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions
  • Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab
  • AstraZeneca and Bristol-Myers Squibb Explore $400B Mega-Merger to Reshape Global Pharma Landscape
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

BrightGene’s Generic Tiotropium Bromide Inhalation Spray Gains NMPA Approval as China’s First Domestic COPD Treatment Alternative

Company Drug

Insilico Medicine’s NLRP3 Inhibitor ISM8969 Secures NMPA IND Approval for Parkinson’s Disease with Global Clinical Trials Underway

Policy / Regulatory

China’s 12th National Drug Volume-Based Procurement Yields Preliminary Winners with Originator Drugs Securing Key Positions

Company Drug

Henlius HLX43 PD-L1 ADC Gains NMPA Approval for Advanced Solid Tumor Trials with Bevacizumab

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.